AKT1 and central nervous system cancer: ACT001, in combination with cisplatin, has shown synergistic effects by suppressing the PAI-1/PI3K/AKT pathway, enhancing apoptosis in glioma cells and overcoming cisplatin resistance (Xi X. et al., 2019).